Characteristics of the pretreatment tumor microenvironment may influence clinical response in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (axi-cel) in the pivotal ZUMA-1

被引：4

作者：

Rossi, John M. ^{[1
]}

Galon, Jerome ^{[2
]}

Turcan, Sarah ^{[3
]}

Danan, Corinne ^{[3
]}

Locke, Frederick L. ^{[4
]}

Neelapu, Sattva S. ^{[5
]}

Miklos, David B. ^{[6
]}

Jacobson, Caron A. ^{[7
]}

Lekakis, Lazaros J. ^{[8
]}

Lin, Yi ^{[9
]}

Ghobadi, Armin ^{[10
]}

Go, William Y. ^{[1
]}

Bot, Adrian ^{[1
]}

机构：

[1] Kite, Santa Monica, CA USA

[2] UPMC Univ Paris, Sorbonne Univ, Univ Paris Descartes, INSERM, Paris, France

[3] HalioDx, Marseille, France

[4] H Lee Moffitt Canc Ctr & Res Inst, Blood & Marrow Transplantat, Tampa, FL USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[6] Stanford Univ, Sch Med, Blood & Marrow Transplantat, Stanford, CA 94305 USA

[7] Dana Farber Canc Inst, Boston, MA 02115 USA

[8] Univ Miami Hlth Syst, Sylvester Comprehens Canc Ctr, Miami, FL USA

[9] Mayo Clin, Div Hematol, Rochester, MN USA

[10] Washington Univ, Sch Med, Div Med Oncol, St Louis, MO USA

来源：

CANCER RESEARCH | 2018年 / 78卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2018-LB-016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LB-016

引用

页数：2

共 50 条

[31] Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel)
Jacobson, Caron
Locke, Frederick L.
Ghobadi, Armin
Miklos, David B.
Lekakis, Lazaros J.
Oluwole, Olalekan O.
Lin, Yi
Braunschweig, Ira
Hill, Brian T.
Timmerman, John M.
Deol, Abhinav
Reagan, Patrick M.
Stiff, Patrick J.
Flinn, Ian W.
Farooq, Umar
Goy, Andre H.
McSweeney, Peter A.
Munoz, Javier
Siddiqi, Tanya
Rossi, John M.
Bot, Adrian
Zheng, Lianqing
Vezan, Remus
Bashir, Zahid
Kim, Jenny J.
Chu, Rong
Neelapu, Sattva S.
BLOOD, 2020, 136
[32] End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma
Jacobson, Caron A.
Locke, Frederick L.
Miklos, David B.
Herrera, Alex F.
Westin, Jason R.
Lee, Jennifer
Rossi, John M.
Zheng, Lianqing
Avanzi, Mauro P.
Roberts, Zachary J.
Sun, Jennifer
BLOOD, 2018, 132
[33] End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma
Jacobson, Caron A.
Locke, Frederick L.
Miklos, David B.
Herrera, Alex F.
Westin, Jason R.
Lee, Jennifer
Rossi, John M.
Sun, Jennifer
Zheng, Lianqing
Avanzi, Mauro P.
Roberts, Zachary J.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
[34] Clinical and biologic covariates of outcomes in ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL).
Locke, Frederick Lundry
Neelapu, Sattva Swarup
Bartlett, Nancy L.
Lekakis, Lazaros J.
Miklos, David Bernard
Jacobson, Caron Alyce
Braunschweig, Ira
Oluwole, Olalekan
Siddiqi, Tanya
Lin, Yi
Timmerman, John
Reagan, Patrick Michael
Bot, Adrian
Rossi, John
Navale, Lynn
Jiang, Yizhou
Aycock, Jeff
Elias, Meg
Wiezorek, Jeffrey S.
Go, William Y.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[35] Axicabtagene Ciloleucel in Patients with Refractory Large B Cell Lymphoma: Outcomes by Prior Lines of Therapy in the Pivotal Phase 2 Study, ZUMA-1
Locke, Frederick L.
Ghobadi, Armin
Lekakis, Lazaros J.
Miklos, David B.
Jacobson, Caron A.
Jacobsen, Eric
Braunschweig, Ira
Oluwole, Olalekan O.
Siddiqi, Tanya
Lin, Yi
Reagan, Patrick M.
Farooq, Umar
Deol, Abhinav
Bot, Adrian
Rossi, John M.
Jiang, Yizhou
Xue, Allen
Go, William Y.
Neelapu, Sattva S.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S276 - S276
[36] Retreatment With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma in ZUMA-5
Chavez, Julio C.
Jacobson, Caron A.
Sehgal, Alison R.
Neelapu, Sattva S.
Maloney, David G.
Salles, Gilles
William, Basem M.
Yang, Yin
Goyal, Lovely
Chou, Justin
Plaks, Vicki
Avanzi, Mauro P.
BLOOD, 2020, 136
[37] Efficacy, safety, and covariates of outcomes with axicabtagene ciloleucel (axi-cel; KTE-C19) from ZUMA-1, a pivotal trial in patients with refractory, aggressive non-Hodgkin lymphoma (NHL)
Lin, Y.
Locke, L.
Neelapu, S. S.
Bartlett, N. L.
Lekakis, L. J.
Miklos, D.
Jacobson, C. A.
Braunschweig, I.
Oluwole, O.
Siddiqi, T.
Timmerman, J.
Reagan, P. M.
Bot, A.
Rossi, J.
Navale, L.
Jiang, Y.
Aycock, J. S.
Elias, M.
Wiezorek, J.
Go, W. Y.
HUMAN GENE THERAPY, 2017, 28 (12) : A5 - A5
[38] Long-Term Follow-Up of ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients With Refractory Aggressive Non-Hodgkin Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (02) : 7 - 9
[39] Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)
Topp, Max S.
van Meerten, Tom
Houot, Roch
Minnema, Monique
Milpied, Noel
Lugtenburg, Pieternella J.
Thieblemont, Catherine
Wermke, Martin
Song, Kevin
Avivi, Irit
Kuruvilla, John
Duehrsen, Ulrich
Chu, Rachel
Zheng, Lianqing
Plaks, Vicki
Kerber, Anne
Kersten, Marie Jose
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S101 - S101
[40] Outcomes by Prior Lines of Therapy in ZUMA-1, the Pivotal Phase 2 Study of Axicabtagene Ciloleucel in Patients With Refractory Large B-Cell Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (08) : 11 - 13

← 1 2 3 4 5 →